Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Buying Up Marijuana Dispensaries
Transcript
- Lucas: Last week a New York-based private equity firm called Pelorus Equity Partners closed on an $85 million acquisition of a 12-store dispensary chain in Michigan. The seller was a family-run operator called Green Labs that had been around since 2019. Luna: That's a big bet on a single state market. Michigan's cannabis sales hit $3 billion last year, but the competition is brutal. Lucas: Right, and that's exactly why PE is moving in. The legal cannabis industry in the US is at this inflection point where federal rescheduling is widely expected by early 2027, and the big operators are positioning themselves to be the dominant players when that happens. Luna: So this is basically a land grab — buying up licenses and storefronts before the federal floodgates open. Lucas: Exactly. But it's not just any licenses. State-level licensing is still the biggest barrier to entry. In Michigan, the Cannabis Regulatory Agency capped the number of Class C grower licenses at 200, and dispensary licenses are just as tight. So when you buy an existing chain, you're buying the license bundle, the real estate, the supply relationships, and the customer base all at once. Luna: And the multiples have gone up. I saw a report from Viridian Capital Advisors that said the median acquisition multiple for dispensaries has gone from about 6x EBITDA in 2024 to roughly 9x now. Lucas: That's a huge jump in less than two years. For context, when PE was rolling up urgent care centers in 2019, multiples were around 7 to 8x. So cannabis is already priced higher, which tells you how much capital is chasing these deals. Luna: What's driving that premium? Is it purely the rescheduling expectation, or is there something else? Lucas: The rescheduling is the big headline, but there's a structural reason too. Most dispensaries are still cash-heavy businesses because of 280E — the tax code that prevents cannabis companies from deducting ordinary business expenses. That crushes profitability. But if rescheduling happens, 280E goes away overnight, and these companies' after-tax income could double or triple. Luna: So PE is buying depressed earnings now, betting on a tax windfall later. Lucas: Exactly right. And they're not just buying the stores — they're buying the infrastructure. Think about it: a dispensary chain has real estate, security systems, inventory management software, delivery logistics, and a regulated supply chain. That's the kind of asset-heavy, cash flow stable business that PE firms love to lever up and optimize. Luna: Okay, but let's talk about the risks, because this isn't a sure thing. The biggest one is regulatory whiplash — what if rescheduling stalls or gets reversed? Lucas: That's the nightmare scenario. If the DEA drags its feet or if a new administration takes a harder line, these companies are stuck with high multiples and the 280E tax burden. Plus, interstate commerce is still banned. So a multi-state operator can't move inventory from one state to another — you have to grow and sell in each state independently. Luna: That kills economies of scale. A chain in five states is basically five separate businesses. Lucas: Right, and that's why some PE firms are focusing on single-state roll-ups. Pelorus, for example, has done two other deals just in Michigan this year. They're trying to dominate one market rather than spread thin. Luna: So what does the actual return profile look like? If you're a limited partner in one of these funds, what are you expecting? Lucas: Typical PE targets are 20 to 25 percent internal rate of return. In cannabis, because of the higher risk, fund managers are pitching 25 to 30 percent. But the holding period is shorter — usually three to five years instead of five to seven — because the rescheduling catalyst is expected within that window. Luna: And the exit? Is it an IPO, a sale to a strategic buyer, or a dividend recap? Lucas: Most are planning for a sale to a larger multi-state operator. The big players like Curaleaf and Green Thumb Industries are cash-rich and looking to acquire. There's also the possibility of a public listing on a major exchange if federal prohibition ends, but that's further out. Luna: Let me ask about the comparison to other roll-ups we've covered. How is this different from, say, the urgent care or veterinary clinic consolidations? Lucas: The big difference is the regulatory overlay. In urgent care, the main barrier was insurance reimbursement and state certificate of need laws. Here, the barrier is federal illegality, which affects banking, taxes, and interstate commerce. It's a much more fragile thesis. Luna: And yet capital is piling in. I saw that just in the first half of 2026, PE firms have raised over $2 billion in dedicated cannabis funds. Lucas: That's a lot of dry powder. And it's coming from traditional firms that never touched cannabis before — names like Cerberus and Blackstone have made small bets. The stigma is fading fast. Luna: But there's also a moral dimension. Some institutional investors still have policies against cannabis because it's federally illegal. So the LP base is narrower. Lucas: True. But that's changing too. Pension funds in states like New York and California have started allocating to cannabis PE. The returns are too attractive for them to ignore, especially with the rescheduling timeline. Luna: So let's zoom back to that Michigan deal. $85 million for 12 stores — that's about $7 million per store. What does that tell us about valuation? Lucas: It tells you that a well-run dispensary with a solid license and a good location is being valued like a small business. For comparison, a Starbucks franchise might sell for $1 to $2 million per location. So these are premium assets because of the license scarcity. Luna: And Green Labs — the seller — they were profitable, right? I think I read they had about $40 million in revenue. Lucas: Yes, they reported $42 million in revenue for 2025 with about $6 million in EBITDA. So the 9x multiple on EBITDA is actually a bit above the median. Pelorus is paying up for the quality of the portfolio. Luna: That makes sense. You buy the best operators first, then optimize the back office. Lucas: Exactly. And that's the playbook: acquire, consolidate, professionalize management, negotiate better supplier terms, and then either hold for the rescheduling pop or sell to a larger platform. Luna: One thing I'm wondering — what happens to the founders? In a lot of these roll-ups, the entrepreneurs get pushed out. But in cannabis, a lot of founders are passionate about the plant and the culture. Lucas: It varies. In the Green Labs deal, the founder stayed on as CEO with a three-year earnout. Pelorus wants his operational knowledge. But in other deals, we see founders cashing out completely. It depends on whether the PE firm thinks the founder can scale. Luna: And that tension — between the culture of cannabis and the efficiency demands of private equity — is one of the more interesting storylines here. Lucas: It really is. You have these mom and pop shops that built a loyal local following, and then a PE firm comes in and standardizes the menu, the pricing, the store layout. Some customers love it, some hate it. Luna: It's the same pattern we saw in veterinary clinics and dental practices. The question is whether the consumer will accept a more corporate experience in cannabis. Lucas: Early data suggests yes — at least for the mainstream customer. The top chains have higher same-store sales growth than independents. But the premium segment, the connoisseurs, they might drift to boutique shops. Luna: So the market might bifurcate, like beer — where you have Bud Light and then craft microbreweries. Lucas: Exactly. And private equity is betting on the Bud Light side. Luna: Alright, so we've covered the deal mechanics, the multiples, the risks, and the cultural tension. But I want to talk about one more thing: the role of federal banking reform. Because right now, most cannabis businesses can't get bank loans or even basic checking accounts. Lucas: That's the SAFE Banking Act — which has been stuck in Congress for years. But with the rescheduling momentum, there's renewed hope. If it passes, it would allow banks to lend to cannabis companies at normal rates. That would reduce the cost of capital for these pe backed chains significantly. Luna: And that would make the returns even more attractive. But it's not baked into the models yet, because it's uncertain. Lucas: Right. The smart firms are modeling two scenarios: one where federal reform happens by 2027, and one where it doesn't. The IRR difference between those scenarios can be 15 percentage points. Luna: That's a huge spread. It means the thesis is very binary. Either you hit the jackpot or you're stuck with a portfolio of cash-heavy, tax-burdened stores. Lucas: Exactly. And that's what makes this episode different from the urgent care or pet cremation roll-ups we talked about earlier. Those were steady, predictable consolidation plays. This one is a high-stakes regulatory bet wrapped in an operational improvement story. Luna: So for our listeners who are thinking about whether to invest in a cannabis PE fund — what's the one thing they should watch? Lucas: Watch the federal register. The DEA's proposed rule on rescheduling is expected to be published for comment this fall. That's the single biggest catalyst. If it moves forward, the multiples will go even higher. If it stalls, the deals will dry up. Luna: And if they're looking for a specific company to track? Lucas: Watch Pelorus Equity Partners. They're aggressive, they're focused on Michigan, and they're a good proxy for how the PE playbook is being applied in cannabis. Luna: I think we should also mention that if these conversations have moved your work forward in some small way, listener support is what keeps this show ad-free. You can find us at buy me a coffee dot com slash fexingo — and it genuinely helps us keep doing deep dives like this one. Lucas: Absolutely. And on that note — the next big date for cannabis PE is actually July 15, when Michigan's next batch of social equity licenses are auctioned. That could shift the competitive landscape. Luna: We'll be watching. Until next time.